{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:50:22Z","timestamp":1777492222206,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019802","name":"BioTechMed-Graz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WE 4388\/6-1"],"award-info":[{"award-number":["WE 4388\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21-AI115207"],"award-info":[{"award-number":["R21-AI115207"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004189","name":"Max-Planck-Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jmb.2019.04.034","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T19:06:41Z","timestamp":1556651201000},"page":"2354-2368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants"],"prefix":"10.1016","volume":"431","author":[{"given":"Nadezhda T.","family":"Doncheva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco S.","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"McGivern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Shimakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lengauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Welsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2019.04.034_bb0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/138920308783565705","article-title":"Proteins as networks: usefulness of graph theory in protein science","volume":"9","author":"Krishnan","year":"2008","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.jmb.2019.04.034_bb0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ddtec.2013.12.003","article-title":"Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development","volume":"11","author":"Welsch","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jmb.2019.04.034_bb0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","article-title":"Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir","volume":"52","author":"Susser","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0025","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0030","doi-asserted-by":"crossref","first-page":"366-76.e6","DOI":"10.1053\/j.gastro.2014.04.006","article-title":"The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis","volume":"147","author":"Manns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmb.2019.04.034_bb0035","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.02606-15","article-title":"Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir\u2013ritonavir and ombitasvir","volume":"60","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2019.04.034_bb0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhep.2015.09.024","article-title":"Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection","volume":"64","author":"Zeuzem","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","article-title":"Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE","volume":"62","author":"Buti","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jmb.2019.04.034_bb0050","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nchembio.1081","article-title":"Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function","volume":"8","author":"Saalau-Bethell","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0060","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1073\/pnas.0408824102","article-title":"Immune evasion by hepatitis C virus NS3\/4A protease-mediated cleavage of the toll-like receptor 3 adaptor protein TRIF","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jmb.2019.04.034_bb0065","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nature04193","article-title":"Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus","volume":"437","author":"Meylan","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2019.04.034_bb0070","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jhep.2014.11.009","article-title":"Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-beta induction by efficient MAVS cleavage","volume":"62","author":"Welsch","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0075","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1128\/JVI.03188-14","article-title":"Protease inhibitors block multiple functions of the NS3\/4A protease\u2013helicase during the hepatitis C virus life cycle","volume":"89","author":"McGivern","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0080","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmb.2019.04.034_bb0085","first-page":"153","volume":"66","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0378-8733(78)90021-7","article-title":"Centrality in social networks conceptual clarification","volume":"1","author":"Freeman","year":"1978","journal-title":"Soc. Networks"},{"key":"10.1016\/j.jmb.2019.04.034_bb0095","series-title":"Network Analysis: Methodological Foundations","first-page":"16","article-title":"Centrality indices","author":"Kosch\u00fctzki","year":"2005"},{"key":"10.1016\/j.jmb.2019.04.034_bb0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.socnet.2004.11.008","article-title":"1. Centrality and network flow.","volume":"27","author":"Borgatti","year":"2005","journal-title":"Soc. Networks"},{"key":"10.1016\/j.jmb.2019.04.034_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrg1272","article-title":"Network biology: understanding the cell's functional organization","volume":"5","author":"Barabasi","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jmb.2019.04.034_bb0110","series-title":"Handbook of Antimicrobial Resistance","article-title":"Protease inhibitor resistance","author":"Vermehren","year":"2015"},{"key":"10.1016\/j.jmb.2019.04.034_bb0115","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/gb-2008-9-1-r16","article-title":"Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus","volume":"9","author":"Welsch","year":"2008","journal-title":"Genome Biol."},{"issue":"44","key":"10.1016\/j.jmb.2019.04.034_bb0120","doi-asserted-by":"crossref","first-page":"29929","DOI":"10.1074\/jbc.M804065200","article-title":"Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase","volume":"283","author":"Beran","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.jmb.2019.04.034_bb0125","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1128\/JVI.00745-14","article-title":"The linker region of NS3 plays a critical role in the replication and infectivity of hepatitis C virus","volume":"88","author":"Kohlway","year":"2014","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.jmb.2019.04.034_bb0130","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nm.3610","article-title":"Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation","volume":"20","author":"Yamane","year":"2014","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jmb.2019.04.034_bb0135","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cell.2009.07.038","article-title":"Protein sectors: evolutionary units of three-dimensional structure","volume":"138","author":"Halabi","year":"2009","journal-title":"Cell."},{"issue":"1","key":"10.1016\/j.jmb.2019.04.034_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1073\/pnas.0805923106","article-title":"Identification of direct residue contacts in protein\u2013protein interaction by message passing","volume":"106","author":"Weigt","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jmb.2019.04.034_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jmb.2019.04.034_bb0150","doi-asserted-by":"crossref","first-page":"12098","DOI":"10.1128\/JVI.01860-14","article-title":"Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus","volume":"88","author":"Sheldon","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmb.2019.04.034_bb0160","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/S0168-8278(15)31102-8","article-title":"P0899: preclinical profile of the pangenotypic HCV NS3\/4A protease inhibitor GS-9857","volume":"62","author":"Taylor","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0165","doi-asserted-by":"crossref","first-page":"D363","DOI":"10.1093\/nar\/gkl970","article-title":"euHCVdb: the European hepatitis C virus database","volume":"35","author":"Combet","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2019.04.034_bb0170","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.01976-13","article-title":"Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir","volume":"58","author":"Berger","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2019.04.034_bb0175","doi-asserted-by":"crossref","first-page":"D36","DOI":"10.1093\/nar\/gks1195","article-title":"GenBank","volume":"41","author":"Benson","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2019.04.034_bb0180","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2019.04.034_bb0185","doi-asserted-by":"crossref","first-page":"W580","DOI":"10.1093\/nar\/gkv279","article-title":"The EMBL-EBI bioinformatics web and programmatic tools framework","volume":"43","author":"Li","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2019.04.034_bb0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/prot.10146","article-title":"Scoring residue conservation","volume":"48","author":"Valdar","year":"2002","journal-title":"Proteins"},{"key":"10.1016\/j.jmb.2019.04.034_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tibs.2011.01.002","article-title":"Analyzing and visualizing residue networks of protein structures","volume":"36","author":"Doncheva","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.jmb.2019.04.034_bb0200","series-title":"Encyclopedia of Distances","author":"Deza","year":"2009"},{"key":"10.1016\/j.jmb.2019.04.034_bb0205","doi-asserted-by":"crossref","first-page":"D475","DOI":"10.1093\/nar\/gks1200","article-title":"The RCSB Protein Data Bank: new resources for research and education","volume":"41","author":"Rose","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2019.04.034_bb0210","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/anie.200906696","article-title":"Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3\/NS4A protease target","volume":"49","author":"Cummings","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jmb.2019.04.034_bb0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0092-8674(00)81351-3","article-title":"Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide","volume":"87","author":"Kim","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2019.04.034_bb0220","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1021\/jm060173k","volume":"50","author":"Prongay","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2019.04.034_bb0225","doi-asserted-by":"crossref","first-page":"7152","DOI":"10.1074\/jbc.275.10.7152","article-title":"Inhibition of the hepatitis C virus NS3\/4A protease. The crystal structures of two protease-inhibitor complexes","volume":"275","author":"Di Marco","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2019.04.034_bb0230","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/pro.5560070402","article-title":"Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 \u00c5 resolution structure in a hexagonal crystal form","volume":"7","author":"Yan","year":"1998","journal-title":"Protein Sci."},{"key":"10.1016\/j.jmb.2019.04.034_bb0235","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0969-2126(00)80025-8","article-title":"Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease\u2013helicase","volume":"7","author":"Yao","year":"1999","journal-title":"Structure"},{"key":"10.1016\/j.jmb.2019.04.034_bb0240","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.00863-07","article-title":"Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease","volume":"52","author":"Zhou","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2019.04.034_bb0245","doi-asserted-by":"crossref","first-page":"22619","DOI":"10.1074\/jbc.M610207200","article-title":"Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha","volume":"282","author":"Zhou","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2019.04.034_bb0250","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1006\/jmbi.1998.2401","article-title":"Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation","volume":"285","author":"Word","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0255","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1006\/jmbi.1998.2400","article-title":"Visualizing and quantifying molecular goodness-of-fit: small-probe contact dots with explicit hydrogen atoms","volume":"285","author":"Word","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0260","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1753-6561-8-S2-S2","article-title":"Integrative visual analysis of protein sequence mutations","volume":"8","author":"Doncheva","year":"2014","journal-title":"BMC Proc."},{"key":"10.1016\/j.jmb.2019.04.034_bb0265","doi-asserted-by":"crossref","first-page":"20483","DOI":"10.1074\/jbc.M500422200","article-title":"Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3\/4A protease","volume":"280","author":"Ferreon","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2019.04.034_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jmb.2019.04.034_bb0275","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1128\/JVI.00377-11","article-title":"Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3\/4A protease","volume":"85","author":"Romano","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0280","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/bioinformatics\/btm554","article-title":"Computing topological parameters of biological networks","volume":"24","author":"Assenov","year":"2008","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jmb.2019.04.034_bb0285","series-title":"Proceedings of the 7th Python in Science Conference (SciPy2008)","doi-asserted-by":"crossref","first-page":"11","DOI":"10.25080\/TCWV9851","article-title":"Exploring network structure, dynamics, and function using NetworkX","author":"Hagberg","year":"2008"},{"key":"10.1016\/j.jmb.2019.04.034_bb0290","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nprot.2012.004","article-title":"Topological analysis and interactive visualization of biological networks and protein structures","volume":"7","author":"Doncheva","year":"2012","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jmb.2019.04.034_bb0295","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","article-title":"Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication","volume":"76","author":"Blight","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0300","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.1128\/JVI.00280-11","article-title":"Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis","volume":"85","author":"Kannan","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2019.04.034_bb0305","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"McGivern","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283619302426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283619302426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:51:30Z","timestamp":1777387890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283619302426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0022283619302426"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2019.04.034","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2019.04.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}